Purple Biotech (PPBT) Common Equity (2017 - 2021)

Purple Biotech (PPBT) has disclosed Common Equity for 5 consecutive years, with $65.1 million as the latest value for Q4 2021.

  • On a quarterly basis, Common Equity fell 18.36% to $65.1 million in Q4 2021 year-over-year; TTM through Dec 2021 was $65.1 million, a 18.36% decrease, with the full-year FY2021 number at $65.1 million, down 18.36% from a year prior.
  • Common Equity was $65.1 million for Q4 2021 at Purple Biotech, down from $79.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $79.8 million in Q4 2020 to a low of $8.7 million in Q4 2017.
  • A 5-year average of $35.1 million and a median of $11.0 million in 2018 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 634.43% in 2020, then dropped 18.36% in 2021.
  • Purple Biotech's Common Equity stood at $8.7 million in 2017, then grew by 26.66% to $11.0 million in 2018, then fell by 1.32% to $10.9 million in 2019, then skyrocketed by 634.43% to $79.8 million in 2020, then decreased by 18.36% to $65.1 million in 2021.
  • Per Business Quant, the three most recent readings for PPBT's Common Equity are $65.1 million (Q4 2021), $79.8 million (Q4 2020), and $10.9 million (Q4 2019).